Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCOPROM
2024-512872-36-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Preterm prelabor rupture of membranes (PPROM) comparing Nifedipine with Placebo (2 arms). Primary endpoint: Composite fetal/neonatal mortality and severe morbidity. Planned start Jul 2024; status: authorised.
02
Drugs
nifedipine
03
Conditions
Preterm prelabor rupture of membranes (PPROM)
Beyond the preview
Go deeper on 2024-512872-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512872-36-00.